dc.contributor.author | Fitton, Catherine A | |
dc.contributor.author | Steiner, Markus F C | |
dc.contributor.author | Aucott, Lorna | |
dc.contributor.author | Pell, J. P. | |
dc.contributor.author | Mackay, Daniel F | |
dc.contributor.author | Fleming, Michael | |
dc.contributor.author | McLay, James S | |
dc.date.accessioned | 2017-07-25T10:00:19Z | |
dc.date.available | 2017-07-25T10:00:19Z | |
dc.date.issued | 2017-11 | |
dc.identifier | 104704202 | |
dc.identifier | 0ec88bfc-2236-407a-9d47-e4196449e32a | |
dc.identifier | 28661961 | |
dc.identifier | 85021692372 | |
dc.identifier.citation | Fitton , C A , Steiner , M F C , Aucott , L , Pell , J P , Mackay , D F , Fleming , M & McLay , J S 2017 , ' In-utero exposure to antihypertensive medication and neonatal and child health outcomes : a systematic review ' , Journal of Hypertension , vol. 35 , no. 11 , pp. 2123-2137 . https://doi.org/10.1097/HJH.0000000000001456 | en |
dc.identifier.issn | 0263-6352 | |
dc.identifier.other | ORCID: /0000-0001-6277-7972/work/84132166 | |
dc.identifier.uri | http://hdl.handle.net/2164/8990 | |
dc.description | ACKNOWLEDGEMENTS We acknowledge the support from the Farr Institute at Scotland. The Farr Institute at Scotland is supported by a 10-funder consortium: Arthritis Research UK, the British Heart Foundation, Cancer Research UK, the Economic and Social Research Council, the Engineering and Physical Sciences Research Council, the Medical Research Council, the National Institute of Health Research, the National Institute for Social Care and Health Research (Welsh Assembly Government), the Chief Scientist Office (Scottish Government Health Directorates), the Wellcome Trust, (MRC Grant No: MR/K007017/1). | en |
dc.format.extent | 15 | |
dc.format.extent | 259753 | |
dc.language.iso | eng | |
dc.relation.ispartof | Journal of Hypertension | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject | adverse drug event | en |
dc.subject | antihypertensive agents | en |
dc.subject | child health | en |
dc.subject | drug exposure in pregnancy | en |
dc.subject | female | en |
dc.subject | hypertension | en |
dc.subject | in-utero exposure | en |
dc.subject | pharmacovigilance | en |
dc.subject | preeclampsia | en |
dc.subject | pregnancy-induced hypertension | en |
dc.subject | R Medicine | en |
dc.subject | Arthritis Research UK (ARUK) | en |
dc.subject | British Heart Foundation | en |
dc.subject | Cancer Research UK | en |
dc.subject | Economic and Social Research Council (ESRC) | en |
dc.subject | Engineering and Physical Sciences Research Council (EPSRC) | en |
dc.subject | Medical Research Council (MRC) | en |
dc.subject | MR/K007017/1 | en |
dc.subject | National Institute for Health Research (NIHR) | en |
dc.subject | Chief Scientist Office (CSO) | en |
dc.subject | Wellcome Trust | en |
dc.subject.lcc | R | en |
dc.title | In-utero exposure to antihypertensive medication and neonatal and child health outcomes : a systematic review | en |
dc.type | Journal article | en |
dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
dc.contributor.institution | University of Aberdeen.Health Services Research Unit | en |
dc.contributor.institution | University of Aberdeen.Farr Aberdeen | en |
dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en |
dc.description.status | Peer reviewed | en |
dc.identifier.doi | 10.1097/HJH.0000000000001456 | |